Description:This patent application embodies vaccine that highlights that glycoproteins and glycolipoproteins of the parasite plasma membrane that exhibit alpha-gal epitopes,which are highly immunogenic to humans. Therefore, patients with cutaneous leishmaniasis and visceral leishmaniasis show high levels of anti-alpha-Gal antibodies.The inventors have proposed anti-alpha-Gal antibodies as a biomarker for detection and follow up of treated leishmaniasis patients. The preliminary results showed partial protection against cutaneous leishmaniasis infection, when alpha 1,3-galactosyltransferase-knockout (alpha 1,3GalT-KO) mice were immunized with a synthetic alpha- Gal-containing neoglycoprotein and challenged with L. major.
Abstract:Certain embodiments are directed to an immunogenic composition comprising an immunogenic glycoconjugate comprising a glycan having the chemical formula of galactopyranose (Galp)-α(1,2)-R, Galp-α(1,3)-R, Galp-α(1,4)-R, or Galp-α(1,6)-R, wherein in R is any monosaccharide, oligosaccharide, or polysaccharide, coupled to a carrier peptide or protein. Certain aspects described herein are directed to compounds and therapies for treating Leishmania infections. In certain aspects, the glycoconjugates as described herein, are incorporated into pharmaceutical compositions or vaccines.
Issue Date: 01/18/2022
Application Date: 09/01/2017
Post Date: 05/15/2018
UTEP Docket No: 2015-042
